Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Year None20262025202420232022 June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy May 26, 2026 Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile May 4, 2026 Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results January 12, 2026 Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference January 7, 2026 Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Minimum 15 minutes delayed. Source: LSEG
Year None20262025202420232022 June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy May 26, 2026 Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile May 4, 2026 Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results January 12, 2026 Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference January 7, 2026 Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
June 1, 2026 Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
May 27, 2026 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
May 26, 2026 Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
March 19, 2026 Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
March 2, 2026 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026 Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026 Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
